On 27 May 2024, Eisai and Biogen announced that South Korea’s Ministry of Food and Drug Safety approved Leqembi® (lecanemab) for treating adults with mild cognitive impairment or mild Alzheimer’s disease.
Leqembi® is reportedly the first approved treatment to reduce disease progression and slow cognitive and functional decline in patients with Alzheimer’s disease. South Korea is the fourth country to approve Leqembi®, following the US in July/2023, Japan in September/2023, and China in January/2024.